Concepts (163)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anti-N-Methyl-D-Aspartate Receptor Encephalitis | 6 | 2026 | 50 | 2.430 |
Why?
|
| Dexamethasone | 3 | 2025 | 249 | 2.350 |
Why?
|
| Encephalitis | 4 | 2025 | 123 | 1.870 |
Why?
|
| Seizures, Febrile | 2 | 2025 | 32 | 1.720 |
Why?
|
| Status Epilepticus | 2 | 2025 | 159 | 1.500 |
Why?
|
| Bradycardia | 1 | 2025 | 57 | 0.910 |
Why?
|
| Receptors, Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2025 | 13 | 0.900 |
Why?
|
| Drug Resistant Epilepsy | 2 | 2025 | 273 | 0.870 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2025 | 55 | 0.860 |
Why?
|
| Cardiac Pacing, Artificial | 1 | 2025 | 134 | 0.850 |
Why?
|
| Clinical Protocols | 1 | 2025 | 229 | 0.820 |
Why?
|
| Microglia | 1 | 2025 | 146 | 0.810 |
Why?
|
| Pacemaker, Artificial | 1 | 2025 | 194 | 0.780 |
Why?
|
| Myelitis | 1 | 2023 | 14 | 0.770 |
Why?
|
| Neuromyelitis Optica | 1 | 2023 | 34 | 0.750 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2025 | 298 | 0.750 |
Why?
|
| B-Lymphocytes | 1 | 2024 | 508 | 0.690 |
Why?
|
| Heart Arrest | 1 | 2025 | 353 | 0.690 |
Why?
|
| Immunotherapy | 3 | 2025 | 758 | 0.670 |
Why?
|
| Myasthenia Gravis | 1 | 2021 | 31 | 0.660 |
Why?
|
| Injections, Spinal | 3 | 2025 | 129 | 0.650 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2025 | 564 | 0.640 |
Why?
|
| Brain Diseases | 1 | 2023 | 298 | 0.640 |
Why?
|
| Hashimoto Disease | 3 | 2025 | 31 | 0.630 |
Why?
|
| Respiratory Insufficiency | 2 | 2017 | 244 | 0.550 |
Why?
|
| Autoantibodies | 4 | 2026 | 435 | 0.540 |
Why?
|
| Multiple Sclerosis | 3 | 2026 | 392 | 0.530 |
Why?
|
| Child | 20 | 2026 | 26166 | 0.510 |
Why?
|
| Pneumonia | 2 | 2017 | 340 | 0.510 |
Why?
|
| Adolescent | 15 | 2026 | 20794 | 0.390 |
Why?
|
| Child, Preschool | 11 | 2026 | 15001 | 0.390 |
Why?
|
| Humans | 32 | 2026 | 130074 | 0.360 |
Why?
|
| Intensive Care Units | 5 | 2025 | 525 | 0.350 |
Why?
|
| Neurodevelopmental Disorders | 3 | 2023 | 629 | 0.340 |
Why?
|
| Retrospective Studies | 11 | 2026 | 17537 | 0.320 |
Why?
|
| Male | 19 | 2026 | 64380 | 0.320 |
Why?
|
| Syndrome | 2 | 2023 | 1157 | 0.320 |
Why?
|
| Down Syndrome | 2 | 2024 | 233 | 0.320 |
Why?
|
| Encephalitis, Herpes Simplex | 2 | 2025 | 20 | 0.280 |
Why?
|
| Female | 18 | 2026 | 70239 | 0.270 |
Why?
|
| Leukoencephalitis, Acute Hemorrhagic | 1 | 2025 | 2 | 0.230 |
Why?
|
| Influenza, Human | 2 | 2025 | 703 | 0.230 |
Why?
|
| Receptor, Macrophage Colony-Stimulating Factor | 1 | 2025 | 11 | 0.230 |
Why?
|
| Rhizomucor | 1 | 2025 | 6 | 0.230 |
Why?
|
| Central Nervous System Fungal Infections | 1 | 2025 | 15 | 0.220 |
Why?
|
| Autoimmune Diseases of the Nervous System | 1 | 2025 | 38 | 0.220 |
Why?
|
| Stroke | 2 | 2025 | 1059 | 0.220 |
Why?
|
| Mucormycosis | 1 | 2025 | 31 | 0.220 |
Why?
|
| Glutamate Decarboxylase | 1 | 2024 | 45 | 0.210 |
Why?
|
| Respiration, Artificial | 2 | 2017 | 500 | 0.210 |
Why?
|
| Lymphocyte Depletion | 1 | 2024 | 124 | 0.210 |
Why?
|
| Transition to Adult Care | 1 | 2026 | 131 | 0.200 |
Why?
|
| Aquaporin 4 | 1 | 2023 | 16 | 0.200 |
Why?
|
| Myelin-Oligodendrocyte Glycoprotein | 1 | 2023 | 35 | 0.200 |
Why?
|
| Spin Labels | 1 | 2023 | 24 | 0.200 |
Why?
|
| Rituximab | 1 | 2024 | 171 | 0.190 |
Why?
|
| Oligodendroglia | 1 | 2023 | 86 | 0.190 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2023 | 124 | 0.180 |
Why?
|
| Phenotype | 4 | 2026 | 4456 | 0.180 |
Why?
|
| Racemases and Epimerases | 1 | 2022 | 12 | 0.180 |
Why?
|
| NADP | 1 | 2022 | 56 | 0.180 |
Why?
|
| Health Status Disparities | 1 | 2025 | 278 | 0.180 |
Why?
|
| NAD | 1 | 2022 | 52 | 0.180 |
Why?
|
| Drug Therapy, Combination | 1 | 2025 | 1165 | 0.170 |
Why?
|
| Pyridostigmine Bromide | 1 | 2021 | 10 | 0.170 |
Why?
|
| Seizures | 2 | 2023 | 874 | 0.170 |
Why?
|
| Sinus Thrombosis, Intracranial | 1 | 2021 | 49 | 0.160 |
Why?
|
| Movement Disorders | 1 | 2023 | 218 | 0.160 |
Why?
|
| Alleles | 1 | 2025 | 1674 | 0.160 |
Why?
|
| Mutation, Missense | 1 | 2025 | 920 | 0.160 |
Why?
|
| Pneumonia, Ventilator-Associated | 2 | 2017 | 33 | 0.160 |
Why?
|
| Influenza Vaccines | 1 | 2025 | 502 | 0.160 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2023 | 289 | 0.160 |
Why?
|
| Metabolic Diseases | 1 | 2022 | 140 | 0.160 |
Why?
|
| Prednisone | 1 | 2021 | 237 | 0.160 |
Why?
|
| Immunoglobulin G | 1 | 2023 | 781 | 0.160 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2021 | 88 | 0.160 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 2024 | 497 | 0.150 |
Why?
|
| Electroencephalography | 1 | 2024 | 848 | 0.150 |
Why?
|
| Blood Pressure | 1 | 2025 | 1344 | 0.150 |
Why?
|
| Biomarkers | 2 | 2026 | 3358 | 0.150 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2021 | 177 | 0.150 |
Why?
|
| Genetic Variation | 1 | 2025 | 1544 | 0.140 |
Why?
|
| Glucocorticoids | 1 | 2021 | 345 | 0.140 |
Why?
|
| Population Surveillance | 1 | 2021 | 393 | 0.140 |
Why?
|
| Genome-Wide Association Study | 1 | 2025 | 1827 | 0.140 |
Why?
|
| Autism Spectrum Disorder | 1 | 2023 | 449 | 0.130 |
Why?
|
| Rhinovirus | 1 | 2017 | 67 | 0.130 |
Why?
|
| Age Factors | 2 | 2021 | 2822 | 0.130 |
Why?
|
| Nervous System Diseases | 1 | 2021 | 392 | 0.120 |
Why?
|
| Hypertension | 1 | 2025 | 1352 | 0.120 |
Why?
|
| Immunosuppressive Agents | 1 | 2021 | 656 | 0.120 |
Why?
|
| Coronavirus Infections | 1 | 2021 | 337 | 0.120 |
Why?
|
| Infant | 5 | 2026 | 13266 | 0.120 |
Why?
|
| Intellectual Disability | 1 | 2023 | 1088 | 0.120 |
Why?
|
| Treatment Outcome | 3 | 2025 | 12818 | 0.120 |
Why?
|
| DNA-Binding Proteins | 1 | 2023 | 1931 | 0.110 |
Why?
|
| Anti-Bacterial Agents | 2 | 2017 | 2574 | 0.110 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2025 | 3407 | 0.110 |
Why?
|
| Disease Progression | 1 | 2021 | 2191 | 0.110 |
Why?
|
| Cholesterol Side-Chain Cleavage Enzyme | 1 | 2014 | 4 | 0.110 |
Why?
|
| Pregnanolone | 1 | 2014 | 8 | 0.110 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2017 | 396 | 0.110 |
Why?
|
| Conditioning, Operant | 1 | 2014 | 13 | 0.110 |
Why?
|
| Alcohols | 1 | 2014 | 14 | 0.100 |
Why?
|
| Cross Infection | 1 | 2017 | 333 | 0.100 |
Why?
|
| Ventral Tegmental Area | 1 | 2014 | 48 | 0.100 |
Why?
|
| Transcription Factors | 1 | 2023 | 2400 | 0.100 |
Why?
|
| Adult | 4 | 2026 | 31011 | 0.100 |
Why?
|
| Bacteria | 1 | 2017 | 521 | 0.100 |
Why?
|
| Pneumonia, Viral | 1 | 2017 | 348 | 0.090 |
Why?
|
| Ethanol | 1 | 2014 | 167 | 0.090 |
Why?
|
| Prospective Studies | 3 | 2017 | 6401 | 0.090 |
Why?
|
| Case-Control Studies | 3 | 2025 | 3349 | 0.090 |
Why?
|
| Brain | 1 | 2023 | 3146 | 0.080 |
Why?
|
| Diagnosis, Differential | 2 | 2026 | 1874 | 0.080 |
Why?
|
| Hospital Mortality | 2 | 2025 | 1057 | 0.060 |
Why?
|
| Middle Aged | 4 | 2026 | 28314 | 0.060 |
Why?
|
| Plasmapheresis | 1 | 2025 | 30 | 0.060 |
Why?
|
| United States | 3 | 2026 | 11894 | 0.060 |
Why?
|
| Influenza B virus | 1 | 2025 | 102 | 0.060 |
Why?
|
| Early Diagnosis | 1 | 2025 | 191 | 0.050 |
Why?
|
| Disability Evaluation | 1 | 2025 | 191 | 0.050 |
Why?
|
| Influenza A virus | 1 | 2025 | 142 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2025 | 5166 | 0.050 |
Why?
|
| Age of Onset | 1 | 2024 | 592 | 0.050 |
Why?
|
| Immunocompromised Host | 1 | 2025 | 310 | 0.050 |
Why?
|
| Muscle Hypotonia | 1 | 2023 | 194 | 0.050 |
Why?
|
| Gait | 1 | 2023 | 141 | 0.050 |
Why?
|
| Social Determinants of Health | 1 | 2024 | 165 | 0.050 |
Why?
|
| Psychometrics | 1 | 2026 | 676 | 0.050 |
Why?
|
| Aged | 2 | 2017 | 20821 | 0.050 |
Why?
|
| Proteomics | 1 | 2026 | 614 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2025 | 1481 | 0.040 |
Why?
|
| Hospitals, Pediatric | 1 | 2026 | 800 | 0.040 |
Why?
|
| Nervous System | 1 | 2021 | 113 | 0.040 |
Why?
|
| Cell Line | 1 | 2025 | 2554 | 0.040 |
Why?
|
| Healthcare Disparities | 1 | 2025 | 514 | 0.040 |
Why?
|
| Activities of Daily Living | 1 | 2022 | 386 | 0.040 |
Why?
|
| Genotype | 1 | 2025 | 2588 | 0.040 |
Why?
|
| Length of Stay | 1 | 2025 | 1406 | 0.040 |
Why?
|
| Developmental Disabilities | 1 | 2023 | 782 | 0.030 |
Why?
|
| Infant, Newborn | 2 | 2021 | 8547 | 0.030 |
Why?
|
| Monobactams | 1 | 2017 | 6 | 0.030 |
Why?
|
| Quinolones | 1 | 2017 | 58 | 0.030 |
Why?
|
| Ceftriaxone | 1 | 2017 | 69 | 0.030 |
Why?
|
| Carbapenems | 1 | 2017 | 45 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2017 | 239 | 0.030 |
Why?
|
| Cephalosporins | 1 | 2017 | 135 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2025 | 2825 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2017 | 422 | 0.030 |
Why?
|
| Mental Disorders | 1 | 2024 | 901 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2026 | 4035 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2017 | 320 | 0.030 |
Why?
|
| Acute Disease | 1 | 2017 | 1153 | 0.030 |
Why?
|
| Self Administration | 1 | 2014 | 49 | 0.030 |
Why?
|
| Rats, Wistar | 1 | 2014 | 298 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2024 | 3739 | 0.020 |
Why?
|
| Motor Activity | 1 | 2014 | 488 | 0.020 |
Why?
|
| Time Factors | 1 | 2021 | 6165 | 0.020 |
Why?
|
| Young Adult | 1 | 2024 | 9978 | 0.020 |
Why?
|
| Rats | 1 | 2014 | 3372 | 0.020 |
Why?
|
| Animals | 2 | 2022 | 33660 | 0.020 |
Why?
|